What is the current stock price of ArriVent BioPharma, Inc. Common Stock (AVBP)?

As of the latest market data, ArriVent BioPharma, Inc. Common Stock (AVBP) is trading at $27.47. The stock has seen a loss of -1.68% today.

Does ArriVent BioPharma, Inc. Common Stock (AVBP) pay a dividend?

Based on current data, ArriVent BioPharma, Inc. Common Stock does not have a confirmed active dividend policy.

What is the market cap of ArriVent BioPharma, Inc. Common Stock?

The current market capitalization of ArriVent BioPharma, Inc. Common Stock (AVBP) is approximately unavailable.

AVBP

ArriVent BioPharma, Inc. Common Stock·Healthcare

27.47

1.682%(−0.47)

Close Price

28.40

3.386%(+0.93)

Pre-Market

Last Updated: — ET

52W L: $16.1052W H: $32.14

AVBP NEWS

seekingalpha.com

May 16

ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case

Management reiterated that the move from early 2026 to mid-2026 was driven by slower event accumulation rather than operational issues, enrollment challenges, or trial redesign. ArriVent ended Q1 with $326.4 million of cash and extended its expected runway from Q3 2027 to Q4 2027, reducing near-term funding risk while supporting late-stage development and commercialization efforts. Shanghai Allist continues to demonstrate strong commercial momentum in China, while ARR-002 adds a new potential growth driver.

globenewswire.com

May 11

ArriVent BioPharma Reports First Quarter 2026 Financial Results

NEWTOWN SQUARE, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent Company progress.

globenewswire.com

May 7

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

NEWTOWN SQUARE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ARR-002, a potential first-in-class MUC16/NaPi2b targeting tetravalent antibody-drug conjugate (ADC) with an initial focus in ovarian and endometrial cancers and broader therapeutic potential across solid tumors.

defenseworld.net

Apr 24

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have issued a buy recommendation

zacks.com

Apr 15

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice

Does ArriVent BioPharma, Inc. (AVBP) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com

Apr 6

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Company Profile

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2024-01-26

Beta

1.52

Websitewww.arrivent.com↗